Search Results

61 - 70 of 89 items :

  • pharmacokinetics x
  • Internal Medicine x
Clear All
Helicobacter pylori treatment results in Slovenia in the period 2013-2015 as a part of European Registry on Helicobacter pylori Management

inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2012; 36 : 414-25. 10.1111/j.1365-2036.2012.05211.x McNicholl AG Linares PM Nyssen OP Calvet X Gisbert JP. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection Aliment Pharmacol Ther 2012 36 414 25 10.1111/j.1365-2036.2012.05211.x 16 Serrano D, Torrado S, Torrado-Santiago S, Gisbert J P. The influence of CYP2C19 genetic polymorphism on the pharmacokinetics/-pharmacodynamics of proton pump inhibitor

Open access
Progress and current status of influenza researches in China

hemagglutinin Cell Host Microbe 2017 22 471 – 83 21 Kadam RU, Juraszek J, Brandenburg B, Buyck C, Schepens WBG, Kesteleyn B, et al Potent peptidic fusion inhibitors of influenza virus. Science 2017; 358: 496–502. Kadam RU Juraszek J Brandenburg B Buyck C Schepens WBG Kesteleyn B et al Potent peptidic fusion inhibitors of influenza virus Science 2017 358 496 – 502 22 Koshimichi H, Ishibashi T, Kawaguchi N, Sato C, Kawasaki A, Wajima T. Safety, tolerability, and pharmacokinetics of the novel anti-influenza agent baloxavir

Open access
Is there a role for contrast-enhanced ultrasound in the detection and biopsy of MRI only visible breast lesions?

. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). Acad Radiol 2008; 15 : 563-70. 10.1016/j.acra.2007.12.014 Giesel FL Choyke PL Mehndiratta A Zechmann CM von Tengg-Kobligk H Kayser K. Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34) Acad Radiol 2008 15 563 70 10.1016/j.acra.2007.12.014 14 Knopp MV, Weiss E, Sinn HP, Mattern J, Junkermann H, Radeleff J, et al

Open access
Viral hepatitis in hemodialysis: An update

standard of care and emerging direct-acting antiviral agents. J Viral Hepat 2012;19:449-64. 166. Peck-Radosavljevic M, Boletis J, Besisik F, Ferraz ML, Alric L, Samuel D, et al. Low-dose peginterferon alfa-2a (40KD) is safe and produces a SVR in patients with chronic hepatitis C and end-stage renal disease. Clin Gastroenterol Hepatol 2011;9:242-8. 167. Glue P, Fang JW, Rouzier-Panis R, Raffanel C, Sabo R, Gupta SK, et al. Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C

Open access
Optimal use of corticosteroids in nephrology

. Bergmann TK, Barraclough KA, Lee KJ, Staatz CE. Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet 2012;51:711-41. 83. Meier-Kriesche HU, Baliga R, Kaplan B. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. Transplantation 2003;75:1291-5. 84. Pascual J, van Hooff JP, Salmela K, Lang P, Rigotti P, Budde K. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with

Open access
Timing of anticoagulation for portal vein thrombosis in liver cirrhosis: A US hepatologist’s perspective

be started within at least 6 months of diagnosis, but shorter delays are preferable where ever possible. Center expertise and patient preference will determine the optimal medical agent and dose until specific dosing and pharmacokinetic data are available in the literature. Because of the above described difficulties in cirrhosis patients with the VKAs, most centers choose LMWH or the DOACs. Patient preference to avoid long term injections often ultimately results in DOAC use in the U.S. Regular surveillance of patients with cross sectional imaging is used to

Open access
Interventional Treatment of Cardiac Emergencies in Children with Congenital Heart Diseases

.1016/j.jcin.2015.05.027. 61. Sivakumar K, Bhagyavathy A, Coelho R, et al. Longevity of neonatal ductal stenting for congenital heart diseases with duct-dependent pulmonary circulation. Congenit Heart Dis. 2012;7:526-533. doi: 10.1111/j.1747-0803.2012.00657.x. 62. Amoozgar H, Cheriki S, Borzoee M, et al. Short-term result of ductus arteriosus stent implantation compared with surgically created shunts. Pediatr Cardiol. 2012;33:1288-1294. 63. Lee K, Seto W, Benson L, et al. Pharmacokinetics of sirolimus-eluting stents implanted in the neonatal arterial

Open access
Molecular biomarkers and histological parameters impact on survival and response to first- line systemic therapy of metastatic colorectal cancer patients

.1093/annonc/mdp206 10.1093/annonc/mdp206 Mir O Ropert S Alexandre J Goldwasser F Hypertension as a surrogate marker for the activity of anti- VEGF agents Ann Oncol 2009 20 967 70 10.1093/annonc/mdp206 37 Poole C, Gardiner J, Twelves C, Johnston P, Harper P, Cassidy J, et al. Effect of renal impairment on the pharmacokinetics and tolarebility of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 2002; 49: 225-34. doi: 10.1007/s00280-001-4808-0 10.1007/s00280-001-0408-0 Poole C Gardiner J Twelves C Johnston P

Open access
Computed tomographic perfusion imaging for the prediction of response and survival to transarterial chemoembolization of hepatocellular carcinoma

. Cardiovasc Intervent Radiol 2012; 35 : 1119-28. 10.1007/s00270-012-0394-0 Malagari K Pomoni M Moschouris H Bouma E Koskinas J Stefaniotou A Chemoembolization with doxorubicin-eluting beads for unresectable hepatocellular carcinoma: five-year survival analysis Cardiovasc Intervent Radiol 2012 35 1119 28 5 Varela M, Real MI, Burrel M, Forner A, Sala M, Brunet M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics . J Hepatol 2007; 46 : 474-81. 10.1016/j.jhep.2006.10.020 Varela M Real MI

Open access
18F-fluorodeoxyglucose and 18F-flumazenil positron emission tomography in patients with refractory epilepsy

–FMZ) have been developed. 55 - 60 Compared to 11 C-FMZ, 18 F-FEFMZ has lower receptor affinity, and higher nonspecific binding due to faster metabolism and faster kinetics. 18 F-FFMZ also has faster kinetics than 11 C-FMZ. Compared to 11 C-FMZ, 18 F-FEF has lower affinity to benzodiazepine receptors, rapid kinetics in the brain and faster metabolism. 55 - 60 18 F-FMZ, with an identical structure to 11 C-FMZ, has been shown to have similar pharmacokinetics and peripheral metabolism and PET imaging characteristics as 11 C-FMZ. 18 F-FMZ has been established as

Open access